Table 2.
Male | Female | |||||
---|---|---|---|---|---|---|
Survivor (n) | Nonsurvivor (n) | P Value | Survivor (n) | Nonsurvivor (n) | P Value | |
Hypercholesterol | 0.089 | 0.270 | ||||
Yes | 457 | 55 | 166 | 33 | ||
No | 355 | 61 | 119 | 33 | ||
Smoking | 0.005a | 0.001a | ||||
Yes | 401 | 40 | 101 | 9 | ||
No | 420 | 75 | 191 | 56 | ||
Diabetes | 0.013a | 0.014a | ||||
Yes | 158 | 34 | 73 | 27 | ||
No | 673 | 81 | 218 | 38 | ||
Hypertension | 0.356 | 0.522 | ||||
Yes | 531 | 82 | 228 | 52 | ||
No | 296 | 37 | 73 | 13 | ||
BMI >30 kg/m2 | 0.834 | 0.557 | ||||
Yes | 239 | 38 | 86 | 17 | ||
No | 612 | 92 | 224 | 54 | ||
EF | <0.0005a | <0.0005a | ||||
>55% | 369 | 13 | 122 | 8 | ||
41%–55% | 287 | 24 | 109 | 15 | ||
31%–40% | 113 | 44 | 46 | 16 | ||
≤30% | 34 | 38 | 9 | 22 | ||
Shock/CPR at time of admission | <0.0005a | <0.0005a | ||||
No | 748 | 67 | 267 | 36 | ||
Yes | 102 | 62 | 43 | 34 | ||
Antiplatelet therapy after 1 year | <0.0005a | <0.0005a | ||||
No ASS/C | 30 | 31 | 13 | 21 | ||
ASS or C | 498 | 2 | 184 | 3 | ||
ASS + C | 247 | 5 | 82 | 2 | ||
Bleeding complications including blood transfusion | 0.096 | 0.007a | ||||
Yes | 6 | 3 | 7 | 7 | ||
No | 833 | 120 | 292 | 63 | ||
Serum creatinine >2 mg/dL (%) | <0.0005a | <0.0005a | ||||
Yes | 18 | 14 | 6 | 10 | ||
No | 819 | 108 | 293 | 55 | ||
Cardiac rehabilitationb | 0.149 | 0.012a | ||||
Yes | 631 | 24 | 216 | 15 | ||
No | 124 | 9 | 43 | 10 |
Abbreviations: BMI, body mass index; C, clopidogrel; CPR, cardiopulmonary resuscitation; EF, ejection fraction; TIMI, Thrombolysis In Myocardial Infarction.
P value (Fisher exact test) is given for comparison between groups.
P<0.05.
Only outpatient data.